Test adding a targeted drug to CHOP for untreated PTCL
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 3 study compares two chemo options—CHOP alone versus CHOP plus AC—for people whose peripheral T-cell lymphoma is the “T-follicular helper” type (PTCL-TFH). The goal is to see which treatment works better for people who have not received lymphoma treatment yet.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can understand the study and sign informed consent before any study steps.
- You are age 18 to 70.
- Your general health is good enough for treatment (ECOG 0–2).
- Your lymphoma has been confirmed by pathology as PTCL-TFH (certain specific subtypes are allowed).
- You have not had prior treatment for PTCL (chemo, targeted therapy, immunotherapy, or lymphoma radiation), except short symptom-relief steroids up to 8 days.
- You have at least one measurable tumor spot (lymph node size and other site sizes must meet criteria).
- Your blood counts, kidney, and liver tests are within study limits.
- If you can become pregnant, you agree to reliable birth control during the study and for 12 months after. Male patients with partners who can become pregnant must also use birth control reliably during treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called golidocitinib added to standard chemotherapy (CHOP) for people newly diagnosed with certain types of T-cell lymphoma. It aims to see if the combination works better than CHOP alone.
This trial studies whether adding chidamide to a combination chemotherapy plan (azacitidine, liposomal mitoxantrone, and prednisone) works better for people newly diagnosed with nodal T-follicular helper (TFH) cell lymphoma. It’s testing a treatment strategy after diagnosis to improve disease control and outcomes.
This Phase 2 trial compares two chemotherapy approaches—adding lenalidomide to CHOP versus CHOP alone—for people with untreated peripheral T-cell lymphoma (PTCL). The goal is to see if the added medicine improves response and safety.
This trial tests a new drug (tucidinostat) added to standard chemotherapy (CHOP) for people newly diagnosed with a specific type of lymphoma called PTCL-TFH. It aims to see if the combination works better than standard treatment alone.
This trial tests whether adding one of two experimental drugs to the standard chemotherapy improves outcomes for people with certain types of peripheral T-cell lymphoma, a rare blood cancer. It aims to see if the combination is safe and effective.
This trial studies azacitidine plus standard CHOP chemotherapy for newly diagnosed nodal T-cell lymphoma that has a specific “TFH” subtype. It aims to improve treatment control for people with this lymphoma type by testing a new combination in an early-phase study.
Hear when a new Peripheral T-cell Lymphoma Targeted Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.